PTC Therapeutics Director Allan Jacobson Sells 1667 Shares for $50.15 Each on 08/28/2025.

PTC Therapeutics, Inc. (PTCT) has announced that Director Jacobson Allan Steven has disposed of 1,667 shares at a price of $50.15 per share on August 28, 2025.

PTC Therapeutics, Inc. (PTCT) has reported that Director Jacobson Allan Steven has sold 1,667 shares of the company's stock on August 28, 2025, at a price of $50.15 per share. This transaction, disclosed in a recent SEC filing, marks a notable move by a high-ranking executive in the biotechnology firm.

The sale comes amidst a period of mixed analyst sentiment and recent regulatory setbacks for PTCT. In August 2025, PTCT received FDA approval for Sephience, an oral treatment for phenylketonuria (PKU), which is expected to drive significant growth. However, the company faced a setback with the FDA issuing a Complete Response Letter for vatiquinone, its oral therapy for Friedreich’s ataxia, citing insufficient efficacy evidence [1].

Despite these challenges, PTCT's strong cash reserves and strategic partnerships with major pharmaceutical companies like Roche and Novartis continue to support the company's long-term prospects. The company's Q2 revenues totaled $179 million, surpassing expectations, and its cash reserves of nearly $2 billion provide financial flexibility for future development [1].

The sale by Director Jacobson Allan Steven, who now owns 337,767 shares valued at approximately $17,476,064.58, represents a 3.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC [2].

Analyst ratings for PTCT remain varied, with a consensus of "Moderate Buy" and a target price of $69.15. However, some analysts have expressed a preference for other AI stocks with greater upside potential and less downside risk [1].

As PTCT navigates these market conditions, investors should closely monitor the company's clinical trial results, regulatory approvals, and financial performance to assess its investment potential.

References:
[1] https://finance.yahoo.com/news/ptc-therapeutics-inc-ptct-faces-085239201.html
[2] https://www.marketbeat.com/instant-alerts/filing-ptc-therapeutics-inc-ptct-stock-holdings-decreased-by-armistice-capital-llc-2025-08-31/